6-Hydroxy-7-methoxydihydroligustilide
CAS No. 210036-09-2
6-Hydroxy-7-methoxydihydroligustilide( —— )
Catalog No. M32197 CAS No. 210036-09-2
6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 270 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name6-Hydroxy-7-methoxydihydroligustilide
-
NoteResearch use only, not for human use.
-
Brief Description6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.
-
Description6-Hydroxy-7-methoxydihydroligustilide is a natural product for research related to life sciences.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number210036-09-2
-
Formula Weight238.3
-
Molecular FormulaC13H18O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
(Phe22)-Big Endothel...
(Phe22)-Big Endothelin-1 fragment (19-37) (human)
-
RMC-7977
RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS with anticancer activity for the study of solid tumors with KRAS G12C mutations.
-
Remimazolam
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
Cart
sales@molnova.com